Valuation: Geron Corporation

Market Cap 628M 566M 523M 472M 894M 58.86B 916M 6.26B 2.5B 31.53B 2.36B 2.31B 100B P/E 2026 *
-43.3x
P/E 2027 * 10.4x
Enterprise Value 628M 566M 523M 472M 894M 58.86B 916M 6.26B 2.5B 31.53B 2.36B 2.31B 100B EV / Sales 2026 *
2.67x
EV / Sales 2027 * 1.86x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+3.16%
1 week-7.47%
Current month+11.73%
1 month-18.09%
3 months-38.69%
6 months-28.11%
Current year-24.30%
1 week 0.93
Extreme 0.929001
1.09
1 month 0.84
Extreme 0.84
1.24
Current year 0.84
Extreme 0.84
2.01
1 year 0.84
Extreme 0.84
2.01
3 years 0.84
Extreme 0.84
5.34
5 years 0.84
Extreme 0.84
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 55 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Free

Director

6,351 0.0010%
30/6/26 Free

Director

6,103 0.0010%
20/5/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+3.16%-7.47%-20.06%-44.48% 628M
-1.06%+9.92%+59.12%+68.61% 68.32B
+1.30%+7.41%+14.79%+90.26% 60.26B
+0.39%+0.30%+20.04%+97.74% 55.86B
-0.64%+11.36%+22.42%+111.56% 48.43B
+0.83%+5.17%+26.95%+43.24% 45.34B
-5.74%-9.13%+183.19%+823.51% 41.76B
+1.97%+9.00%+25.20%+50.98% 34.5B
-0.56%-0.48%+85.57%+57.71% 33.8B
-1.49%+13.52%+43.09%+0.06% 25.96B
Average -0.21%+4.59%+46.03%+129.92% 41B
Weighted average by Cap. -0.50%+4.04%+50.32%+147.09%

Financials

2026 *2027 *
Net sales 235M 212M 196M 177M 335M 22.07B 343M 2.35B 936M 11.82B 883M 864M 37.62B 338M 305M 282M 254M 481M 31.71B 493M 3.37B 1.34B 16.98B 1.27B 1.24B 54.04B
Net income -14.25M -12.85M -11.87M -10.73M -20.3M -1.34B -20.8M -142M -56.7M -716M -53.5M -52.36M -2.28B 62.34M 56.18M 51.91M 46.92M 88.78M 5.85B 90.97M 622M 248M 3.13B 234M 229M 9.96B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
12/11/26 US$0.9996 +2.61% 3,131,356
10/11/26 US$0.9742 -2.24% 12,511,393
09/11/26 US$0.9965 +0.68% 5,732,297
06/11/26 US$0.9898 +4.18% 13,652,175
05/11/26 US$0.9501 -12.03% 25,833,003
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.9742USD
Average target price
3.500USD
Spread / Average Target
+259.27%
  1. Stock Market
  2. Stocks
  3. GERN Stock